+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

Visiongain Publishes Animal Model Market Report to 2031

15 March 2021

Visiongain has published a new report on Animal Model Market Report to 2031: Forecasts by Animal Type (Mice, Rats, Fish, Birds, Cattle, Pigs, Amphibians, Guinea Pigs, Dogs, Cats, Rabbits, Monkeys, Sheep, Hamsters), By Technology (CRISPR, Microinjection, Embryonic Stem Cell, Nuclear Transfer), By Application (Research & Development {Infectious Disease, Immunological Disease, Cancer, Cardiovascular Diseases, Diabetes, Genetic Diseases, Neurological Diseases}, Production And Quality Control, Academics), By Use (Human, Veterinary), By End-use (Companies {Pharmaceutical, Biotechnology, Cosmetics}, Organizations {Government, Non-Government}, Academic And Research Institutes, Contract Research Organizations) PLUS COVID-19 Recovery Scenarios.

Global Animal Model market size is projected to reach US$ XX Million in 2021 and is expected to display strong revenue growth through to 2031.

COVID-19 Impact on Animal Model Market
The pandemic has posed an exceptional worldwide public health challenge and is anticipated to have a major impact on the animal model market. A large number of animal models are essential for the research & development of antiviral drugs and vaccines. Besides, they are used to validate the safety and efficiency of new drug candidates before proceeding to human trials. As per the World Health Organization, over 20 shots of vaccines are being developed for COVID-19 worldwide. These candidates are in the preclinical stage, and few of them have now entered the animal trials phase.

Nevertheless, the present supply is restricted, as animal model suppliers do not have enough animal breeds to meet growing demand. Moreover, due to unplanned lockdowns in many countries, various research institutions and academics are shut off and are inept to work generally, which has unpleasantly affected the animal model market.

Seeing the scenario as described above, the pandemic is expected to damage the animal model market growth in the short term. Though, in the long term, scientific research institutions and government organizations in many countries are certain to upsurge research funding in therapies and vaccines against COVID-19. The growing demand for pharmaceutical drugs and vaccines is anticipated to lift the animal model market growth in the given timeframe.

Market Drivers

Growing Use of Animal Models in Virology and Infectious Diseases
In the past few years, there has been a growth in the occurrence of infectious diseases. In the previous two decades, coronavirus occurred three times i.e. SARS-CoV outbreak took place in 2002, whereas MERS-CoV was in 2012, and presently SARS-CoV-2 in 2019. Though, the recent SARS-CoV-2 is considerably more harmful than the previous two outbreaks and has affected over 213 countries across the world infecting millions of people. The arrival of the SARS-CoV-2 in 2019 has encouraged the use of animal models for the research purpose of its pathology and to develop an effective cure against it.

Apart from SARS-CoV-2 research, animal models are well known for the cytomegalovirus (CMV), hepatitis B virus (HBV), Zika virus, and hepatitis C virus (HCV), among others. As per the World Health Organization, above 17 million people caused death by infectious diseases annually. In the past few decades, more than 30 novel infectious diseases have appeared across the world. According to UNAIDS, 38 million individuals were affected by HIV by the end of 2019, thus, animal models have been broadly used for numerous viral studies.

Rising Demand for Personalized Medicine Will Augment the Animal Model Market
The growing use of personalized medicine has increased the demand for humanized mouse models to treat some diseases such as Amyotrophic Lateral Sclerosis and Alzheimer’s. According to data published by the National Institute of Aging, the humanized mouse model permits precision medicine investigation for psychological conditions including Alzheimer’s disease. The study discovered that the maximum molecular structures of Alzheimer’s disease can be reproduced in a humanized mouse model that will help to rises the investigation for personalized medicine concerning Alzheimer’s disease.

Market Opportunities

Growing Demand for Humanized Mice Models
Humanized mice models are significant tools for preclinical research to improved understandings of human biology. These humanized mice models are advanced through the stem cell engraftment of human tissues, causing the expression of human proteins in the target mice model.

Humanized mice are progressively being used in biomedical research applications, such as infectious diseases, regenerative medicine, HIV/AIDS, cancer, and hepatitis. For instance, in March 2019, the National Institute of Allergy and Infectious Diseases (NIAID) publicized funding for research projects to conduct complete characterization, straight evaluations, and additional advanced of humanized immune system (HIS) mice models. The necessity to find the actual effects of pharmaceutical drugs on humans, along with the rising focus on the investigation of human-specific infections, immune responses, and therapies, is endorsing the growth of the target industry.

Competitive Landscape
Key players operating in the global Animal Model market are Janvier Labs, Envigo, Transgenic, Inc., Charles River Laboratories, GenOway S.A., Taconic Laboratories, Horizon Discovery, Crown Bioscience Inc., SAGE Labs, and Harbor Antibodies Bv.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

12 April 2024


Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034

The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.

11 April 2024


Visiongain Publishes Female Health Tech Market Report 2024-2034

The global Female Health Tech market was estimated to be valued at US$ 140.9 billion in 2034 and is expected to register a CAGR of 9.6% from 2024 to 2034.

05 April 2024


Visiongain Publishes Meningococcal Vaccines Market Report 2024-2034

The global Meningococcal Vaccines market is projected to grow at a CAGR of 2.5% by 2034

26 March 2024